Last reviewed · How we verify

PrECOG, LLC. — Portfolio Competitive Intelligence Brief

PrECOG, LLC. pipeline: 0 marketed, 0 filed, 2 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 4 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Arm B: Daratumumab Hyaluronidase Arm B: Daratumumab Hyaluronidase phase 3 CD38-targeting monoclonal antibody CD38 Oncology
Arm A: Belantamab Mafodotin Arm A: Belantamab Mafodotin phase 3 Antibody-drug conjugate (ADC) BCMA (B-cell maturation antigen) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Charite University, Berlin, Germany · 2 shared drug classes
  2. Janssen Research & Development, LLC · 2 shared drug classes
  3. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  4. BioAtla, Inc. · 1 shared drug class
  5. Byondis B.V. · 1 shared drug class
  6. Celltrion · 1 shared drug class
  7. AstraZeneca · 1 shared drug class
  8. Ascentage Pharma Group Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for PrECOG, LLC.:

Cite this brief

Drug Landscape (2026). PrECOG, LLC. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/precog-llc. Accessed 2026-05-14.

Related